Drug Profile
Efpeglenatide - Hanmi Pharmaceutical/Sanofi
Alternative Names: HM-11260C; Langlenatide; LAPS-Exd4; LAPS-Exendin; LAPS-exendin 4 analogue; LAPS-Exendin4; LAPSCA-Exendin4; SAR-439977Latest Information Update: 29 Dec 2023
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Developer Hanmi Pharmaceutical; Sanofi
- Class Antihyperglycaemics; Immunoglobulin Fc fragments; Obesity therapies; Peptides; Polyethylene glycols; Pyrrolidines; Recombinant proteins
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 18 Dec 2023 Hanmi Pharmaceutical Company plans phase III trial in Obesity (NCT06174779)
- 13 Nov 2021 Efficacy and safety data from the phase III AMPLITUDE-O trial in Type 2 diabetes mellitus presented at the American Heart Association Scientific Sessions 2021 (AHA-2021)
- 29 Jun 2021 Sanofi terminates its licence for Efpeglenatide in the year 2020